Billionaire David E. Shaw's 10 Small-Cap Stock Picks with Huge Upside Potential
David E. Shaw is one billionaire investor whose record speaks for itself on Wall Street. Having founded D.E. Shaw & Co., L.P.
Ptc Therapeutics Inc. (PTCT)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Neo Ivy Capital Renee Yao | 36,246 | $1,847,096 | 0.59% | |
| 2. | Quantinno Capital Hoon Kim | 8,586 | $437,543 | -12% | 0% |
| 3. | Bayforest Capital Theodoros Tsagaris | 8,153 | $257,297 | 0.21% | |
| 4. | Entropy Technologies Vikram Modi And Arjun Modi | 4,492 | $228,912 | 0.02% | |
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.81 | 7,700 | 33,700 | 2023-12-12 | Filing | ||
| $32.48 | 10,000 | Director | 100,066 | 2020-03-16 | Filing | |
| $30.20 | 66,225 | Director | 1,386,594 | 2019-01-25 | Filing | |
| $13.49 | 25,000 | Director | 25,000 | 2017-05-23 | Filing | |
| $6.23 | 2,000 | Officer | 5,125 | 2016-03-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $48.74 | 2,804 | 273,234 | 2025-04-22 | Filing | ||
| $46.95 | 897 | 75,997 | 2025-04-02 | Filing | ||
| $58.31 | 300 | 72,640 | 2025-03-17 | Filing | ||
| $57.67 | 3,340 | 72,940 | 2025-03-17 | Filing | ||
| $56.62 | 1,085 | 76,280 | 2025-03-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,607,372 | $438,631,678 | 0.01% | |
| 2. | 7,768,217 | $395,868,338 | 0.01% | |
| 3. | 2,013,562 | $102,611,119 | 0.01% | |
| 4. | 1,042,458 | $54,011,142 | 0.06% | |
| 5. | 1,009,168 | $51,427,201 | 0.02% |
News See All
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the PTC Therapeutics First Quarter 2025 Earnings Conference Call. [Operator Instructions] Today’s conference is being recorded.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the PTC Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants are in listen only mode.
Why PTC Therapeutics (PTCT) Stock Is Rallying Today
The bank believes that, in the wake of the results from the Phase 3 trial of PTCT's drug known as Sepiapterin, the product is viewed as likely to be approved by the FDA.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2024 Earnings Call Transcript
Operator: Welcome to the PTC Third Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to PTC Second Quarter 2024 Financial Results Conference Call.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript
PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.2, expectations were $-1.31. PTC Therapeutics, Inc.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript
PTC Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $0.29.
Analysts on Wall Street Lower Ratings for These 5 Stocks
On December 19, Morgan Stanley analyst Jeffrey Hung downgraded PTC Therapeutics, Inc. (NASDAQ:PTCT) from Equalweight to Underweight, within the biotechnology industry.